Pretreatment serum HBsAg-to-HBV DNA ratio predicts a virologic response to entecavir in chronic hepatitis B
2
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
Background/Aims: Decay of hepatitis B surface antigen (HBsAg) titers has previously been shown to be predictive of a virologic response (VR), especially during peginterferon-alpha therapy. However, the role of HBsAg levels in predicting a VR to nucleos(t)ide analog therapy has not yet been established. In this study we sought to determine whether the VR can be predicted from HBsAg titers in nucleos(t)ide-naïve chronic hepatitis B (CHB) patients treated with entecavir. Methods: CHB patients who started entecavir as an initial antiviral therapy were enrolled in this study. Serum hepatitis B virus (HBV) DNA, HBsAg, and alanine aminotransferase levels were measured every 3 months during treatment. A VR was defined as undetectable serum HBV DNA titer by real-time PCR assay (<60 IU/mL). Results: Fifty-two patients were enrolled, and the median duration of treatment was 26 months (range 7-35 months). Forty-five patients achieved a VR; the cumulative VR rates at 3, 6, 12, and 24 months were 40%, 71.2%, 81.5%, and 88%, respectively. Baseline HBV DNA levels were significantly lower in patients with VR, whereas the HBsAg levels did not differ significantly between patients with or without VR. In a univariate analysis the cumulative VR rate was significantly higher in HBeAg negative patients and patients with an HBsAg/HBV DNA ratio above 0.56. However, in a multivariate analysis only an HBsAg/HBV DNA ratio above 0.56 was an independent predictor of VR (P=0.003). The area under the receiver operating characteristic curve was larger for the HBsAg/HBV DNA ratio than for either HBV DNA or HBsAg. Conclusions: Pretreatment HBsAg/HBV DNA ratio can predict a long-term VR to entecavir therapy in nucleos(t)ide-naïve CHB patients.
Abstract
Background/Aims: Decay of hepatitis B surface antigen (HBsAg) titers has previously been shown to be predictive of a virologic response (VR), especially during peginterferon-alpha therapy. However, the role of HBsAg levels in predicting a VR to nucleos(t)ide analog therapy has not yet been established. In this study we sought to determine whether the VR can be predicted from HBsAg titers in nucleos(t)ide-naïve chronic hepatitis B (CHB) patients treated with entecavir. Methods: CHB patients who started entecavir as an initial antiviral therapy were enrolled in this study. Serum hepatitis B virus (HBV) DNA, HBsAg, and alanine aminotransferase levels were measured every 3 months during treatment. A VR was defined as undetectable serum HBV DNA titer by real-time PCR assay (<60 IU/mL). Results: Fifty-two patients were enrolled, and the median duration of treatment was 26 months (range 7-35 months). Forty-five patients achieved a VR; the cumulative VR rates at 3, 6, 12, and 24 months were 40%, 71.2%, 81.5%, and 88%, respectively. Baseline HBV DNA levels were significantly lower in patients with VR, whereas the HBsAg levels did not differ significantly between patients with or without VR. In a univariate analysis the cumulative VR rate was significantly higher in HBeAg negative patients and patients with an HBsAg/HBV DNA ratio above 0.56. However, in a multivariate analysis only an HBsAg/HBV DNA ratio above 0.56 was an independent predictor of VR (P=0.003). The area under the receiver operating characteristic curve was larger for the HBsAg/HBV DNA ratio than for either HBV DNA or HBsAg. Conclusions: Pretreatment HBsAg/HBV DNA ratio can predict a long-term VR to entecavir therapy in nucleos(t)ide-naïve CHB patients.
참고문헌 (28)
- Lok AS, "Chronic hepatitis B: update 2009", Hepatology, 50, pp.661~662 (2009)
- Nguyen MH, "Chronic hepatitis B: early viral suppression and long-term outcomes of therapy with oral nucleos(t)ides", J Viral Hepat, 16, pp.149~155 (2009)
- Keeffe EB, "Report of an international workshop: Roadmap for management of patients receiving oral therapy for chronic hepatitis B", Clin Gastroenterol Hepatol, 5, pp.890~897 (2007)
- Yuen MF, "Factors associated with hepatitis B virus DNA breakthrough in patients receiving prolonged lamivudine therapy", Hepatology, 34, pp.785~791 (2001)
- Yuen MF, "Hepatitis B virus DNA levels at week 4 of lamivudine treatment predict the 5-year ideal response", Hepatology, 46, pp.1695~1703 (2007)
- 김동준, "Telbivudine versus lamivudine in patients with chronic hepatitis B", NEW ENGLAND JOURNAL OF MEDICINE, 357(25), pp.2576~2588, MASSACHUSETTS MEDICAL SOC
- Chan HL, "Treatment of hepatitis B e antigen positive chronic hepatitis with telbivudine or adefovir: a randomized trial", Ann Intern Med, 147, pp.745~754 (2007)
- Zeuzem S, "Baseline characteristics and early on-treatment response predict the outcomes of 2 years of telbivudine treatment of chronic hepatitis B", J Hepatol, 51, pp.11~20 (2009)
- Ghany MG, "Antiviral resistance and hepatitis B therapy", Hepatology, 49, pp.174~184
- Tenney DJ, "Long-term monitoring shows hepatitis B virus resistance to entecavir in nucleoside-naïve patients is rare through 5 years of therapy", Hepatology, 49, pp.1503~1514 (2009)
- Chang TT, "A comparison of entecavir and lamivudine for HBeAg-positive chronic hepatitis B", N Engl J Med, 354, pp.1001~1010 (2006)
- 한광협, "Entecavir therapy for up to 96 weeks in patients with HBeAg-Positive chronic hepatitis B", GASTROENTEROLOGY, 133, pp.1437~1444, W B SAUNDERS CO-ELSEVIER INC
- Chon YE, "Partial virological response to entecavir in treatment-naive patients with chronic hepatitis B", ANTIVIRAL THERAPY, 16(4), pp.469~477 (2011)
- 명형준, "만성 B형간염 환자에 대한 초치료제로서 엔테카비어의 항바이러스 효과와 그 예측인자", Clinical and Molecular Hepatology, 16(1), pp.57~65 (2010), 대한간학회
- Brunetto MR, "Hepatitis B virus surface antigen levels: a guide to sustained response to peginterferon alfa-2a in HBeAg-negative chronic hepatitis B", Hepatology, 49, pp.1141~1150 (2009)
- Moucari R, "Martinot-Peignoux M, et al. Early serum HBsAg drop: a strong predictor of sustained virological response to pegylated interferon alfa-2a in HBeAg-negative patients", Hepatology, 49, pp.1151~1157 (2009)
- Rijckborst V, "Early on-treatment prediction of response to peginterferon alfa-2a for HBeAg-negative chronic hepatitis B using HBsAg and HBV DNA levels", Hepatology, 52, pp.454~461 (2010)
- Cai W, "On-treatment serum HBsAg level is predictive of sustained off-treatment virologic response to telbivudine in HBeAg-positive chronic hepatitis B patients", J Clin Virol, 48, pp.22~26 (2010)
- Wursthorn K, "Kinetics of hepatitis B surface antigen decline during 3 years of telbivudine treatment in hepatitis B e antigen-positive patients", Hepatology, 52, pp.1611~1620 (2010)
- Jung YK, "Change in serum hepatitis B surface antigen level and its clinical significance in treatment-naïve, hepatitis B e antigen-positive patients receiving entecavir", J Clin Gastroenterol, 44, pp.653~657 (2010)
- Lee JM, "Quantitative Hepatitis B Surface Antigen and Hepatitis B e Antigen Titers in Prediction of Treatment Response to Entecavir", HEPATOLOGY, 53(5), pp.1486~1493, JOHN WILEY & SONS INC
- European Association For The Study Of The Liver, "EASL Clinical Practice Guidelines: management of chronic hepatitis B", J Hepatol, 50, pp.227~242 (2009)
- DeLong ER, "Comparing the areas under two or more correlated receiver operating characteristic curves: a nonparametric approach", Biometrics, 44, pp.837~845 (1988)
- Manesis EK, "Prediction of treatment-related HBsAg loss in HBeAG-negative chronic hepatitis B: a clue from serum HBsAg levels", Antivir Ther, 12, pp.73~82 (2007)
- Nguyen T, "Hepatitis B surface antigen levels during the natural history of chronic hepatitis B: a perspective on Asia", J Hepatol, 52, pp.508~513 (2010)
- Jaroszewicz J, "Hepatitis B surface antigen (HBsAg) levels in the natural history of hepatitis B virus (HBV)-infection: a European perspective", J Hepatol, 52, pp.514~522 (2010)
- Thompson AJ, "Serum hepatitis B surface antigen and hepatitis B e antigen titers: disease phase influences correlation with viral load and intrahepatic hepatitis B virus markers", Hepatology, 51, pp.1933~1944 (2010)
- Brunetto MR, "A new role for an old marker, HBsAg", J Hepatol, 52, pp.475~477 (2010)